Moul, Judd W. https://orcid.org/0000-0001-9228-8344
Shore, Neal D.
Pienta, Kenneth J. https://orcid.org/0000-0002-4138-2186
Czernin, Johannes
King, Martin T.
Freedland, Stephen J. https://orcid.org/0000-0002-8104-6419
Funding for this research was provided by:
Pfizer Inc. and Astellas Pharma Inc.
Article History
Received: 23 February 2023
Revised: 27 July 2023
Accepted: 3 August 2023
First Online: 7 September 2023
Change Date: 17 January 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41391-024-00791-6
Competing interests
: J.W.M.: Stock or Other Ownership: AstraZeneca, Bavarian Nordic, Eli Lilly and Company, Johnson & Johnson, Novartis, Pfizer, Procter & Gamble, Theralogix LLC, Walgreens; Honoraria: AbbVie, Astellas Pharma, Bayer, Ferring Pharmaceuticals, Dendreon Pharmaceuticals, GenomeDx Biosciences, Genomic Health, Janssen, Pfizer, Sanofi; Consulting or Advisory Role: AbbVie, Bayer, Blue Earth Diagnostics Ltd, Theralogix LLC, Tolmar Inc.; Speakers’ Bureau: Bayer, Ferring Pharmaceuticals, Dendreon Pharmaceuticals, GenomeDx Biosciences, Genomic Health, Janssen, Sanofi; Research Funding: Astellas Pharma (Inst), Pfizer (Inst). N.D.S.: Grant Support and Consulting Fees: AbbVie, Amgen, Astellas Pharma, Bayer, Dendreon Pharmaceuticals, Ferring Pharmaceuticals, Janssen Oncology, Pfizer, Sanofi–Genzyme, and Tolmar Inc. K.J.P.: Founder and Equity Holder: Keystone Biopharma, Inc.; Consultant: Cue Biopharma, Inc.; Research Funding: Progenics Pharmaceuticals, Inc. J.C.: Founder, Board Member, and Equity Holder: Sofie Biosciences, Trethera Therapeutics; Advisory Board Member: Actinium Pharmaceuticals Inc, Aktis Oncology, Amgen, Jubilant Radiopharma. M.T.K.: Grant Support and Consulting Fees: Bayer, Palette Life Sciences. S.J.F.: Consultant: Astellas Pharma, AstraZeneca, Bayer, Dendreon Pharmaceuticals, Janssen, Merck, Myovant Sciences, Pfizer, Sanofi.